Abstract

Interstitial lung disease (ILD) is one of the most serious pulmonary complications associated with connective tissue diseases (CTDs). While immunosuppressants are commonly prescribed in these patients, evidence supporting their efficacy in slowing lung function decline is limited, especially when compared to or combined with antifibrotics, and practices vary. This study aims to describe the prevalence of ILD-treating therapies, such as immunosuppressants and antifibrotics, in patients with CTD-ILD following their ILD diagnosis.